Hormone-therapy mediated interactions between platelets and breast cancer cells: an in vitro study
No Thumbnail Available
Date
2020
Authors
Pather, Kyrtania
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Breast cancer-associated thrombosis is a growing concern. Reciprocal interactions between
platelets and tumour cells facilitate tumour progression, ultimately leading to
thromboembolic complications. Treatment strategies including hormone-therapies are
associated with increased thrombotic risk. However, in vitro studies found that Tamoxifen
reduces thrombotic risk, contradictory to clinical evidence; with little evidence on the
mechanistic effects of Anastrozole. Furthermore, while hormone-dependent tumours are
treated with hormone therapy based on the presentation of the oestrogen receptor (ER), ERα,
little is understood regarding ERβ. This study developed an in vitro system to mimic the effects
of cumulative hormone-therapy (Anastrozole or Tamoxifen) by pre-treating MCF7 and T47D
cells with hormone-therapy (Model 1) prior to exposure to whole blood (WB).
Early stages of platelet activation described using CD62P expression and ultrastructure, and
associated cancer cell ER (ESR1 and ESR2) gene expression were assessed. The study was then
expanded to include an additional model to recapitulate circulatory effects of hormone therapy (Model 2) where blood constituents (WB, platelet-rich plasma and platelet-poor
plasma) were pre-treated prior to exposure to cancer cells. Hypercoagulation was assessed
as a function of thrombin activity, CD62P and CD63 expression defined by an index of platelet
activation, and corresponding ultrastructure. Furthermore, ER protein expression was
determined and correlated with hypercoagulation markers to assess whether tumour profiles
and hypercoagulation were associated.
Breast cancer cells induced hypercoagulation, compounded by hormone-therapy regardless
of Model employed, but dependent on cellular subphenotype. Furthermore, ER expression
altered, highlighting subphenotypic differences; with T47D cells, having greater ERβ
expression. We postulate this profile is associated with the induction of a hypercoagulatory
environment under Anastrozole treatment. Additionally, it was determined that Tamoxifen
treatment induces a hypercoagulatory environment. This not only compares with clinical
studies indicating a greater thrombotic risk for patients undergoing hormone-therapy
treatment but highlights that subphenotypes, which clinically would be treated similarly, may
be associated with differing thromboembolic profiles.
The present study provides a framework and ex vivo models in which to undertake further
research, to complement our findings regarding breast tumour subphenotype heterogeneity
and to determine other biomarkers that may be predictive of hypercoagulatory risk
Description
A thesis submitted in fulfilment of the requirements for the degree of
Doctor of Philosophy to the Faculty of Health Sciences,
School of Anatomical Sciences, University of the Witwatersrand, Johannesburg, 2020